Lucia B. Jilaveanu

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Sarah B. Goldberg, Scott Gettinger, Amit Mahajan et al. · The Lancet Oncology · 2016 · 987 citations · Full text

Neuro-oncology, Non-small-cell Lung Cancer, Untreated Brain Metastases +8

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

Sarah B. Goldberg, Kurt A. Schalper, Scott Gettinger et al. · The Lancet Oncology · 2020 · 523 citations · Full text

Neuro-oncology, Prognostic Biomarkers, Biomarker Analysis +11

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

Harriet M. Kluger, Veronica Chiang, Amit Mahajan et al. · Journal of Clinical Oncology · 2018 · 275 citations

KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements

Shang‐Min Zhang, Wesley L. Cai, Xiaoni Liu et al. · Nature · 2021 · 245 citations · Full text

Immunogenetics, Immune Evasion, Adaptive Immune System +6

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

Harriet M. Kluger, Christopher R. Zito, Meaghan L. Barr et al. · Clinical Cancer Research · 2015 · 201 citations · Full text